Tolerance and Effectiveness of Cell Therapy by Autologous Apoptotic Cells in the Treatment of Rheumatoid Arthritis

Inclusion Criteria: * Patients with a diagnosis of Rheumatoid arthritis * Therapy failure with at least one biological agent from anti-TNF-alpha (etanercept, infliximab, adalimumab, certolizumab and golimumab; 3 months at optimal dose), anti-IL6 (tocilizumab; 3 months); T-cell costimulatory pathway inhibitor (abatacept; 3 months); anti-CD20 (rituximab; 6 months at optimal dose); Anti IL-1 (anakinra; 3 months) * Disease Activity Score (DAS) DAS28 ≥ 3.2 * Subject has provided written informed consent Exclusion Criteria: * Pregnant or lactating women * Inflammatory arthritis other than rheumatoid arthritis * History of invasive cancer * Immunodeficiency (HIV infection, Immunosuppressive therapy) * Active bacterial or viral infections, in particular HCV or HBV. * Surgery not older than 4 weeks. * Unstable comorbidities: uncontrolled diabetes, heart disease, advanced renal or hepatic impairment. * Contraindication to an apheresis